Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Linagliptin Stories

2014-04-14 12:34:34

RIDGEFIELD, Conn. and INDIANAPOLIS, April 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) accepted the filing of the New Drug Application (NDA) for the investigational combination tablet of empagliflozin and linagliptin for the treatment of adults with type 2 diabetes (T2D). If granted approval by the FDA, this combination will bring together, for the first time into...

2013-10-31 23:31:05

MarketResearch.com announces the addition of a new market research report in Pharmaceuticals to their product offering: Type 2 Diabetes Market to 2019 http://www.marketresearch.com/land/product.asp?productid=7840706&progid=85831. Rockville, MD (PRWEB) October 31, 2013 Type 2 Diabetes Therapeutics Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 The global type 2 diabetes market is expected to grow from $20.4 billion in 2012...

2013-09-30 08:26:11

NEW YORK, September 30, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Investors' Reports announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Eli Lilly & Company (NYSE: LLY), AbbVie Inc. (NYSE: ABBV), and GlaxoSmithKline plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry...

2013-09-24 08:29:46

Two pooled analyses of data from clinical trials in adults with type 2 diabetes, including the elderly with normal renal function to severe renal impairment, found similar incidence of adverse events for linagliptin compared with placebo RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 24, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the...

2013-09-17 08:31:21

Presentations at EASD to include safety and efficacy data for the Diabetes Alliance compounds RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 17, 2013 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (Lilly; NYSE: LLY) today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin(^) at the 49(th) Annual Meeting of the European Association for the Study of Diabetes (EASD), which will take place in Barcelona from...

2013-08-15 12:28:10

Phase III safety and efficacy data of TRADJENTA® (linagliptin) tablets in elderly people with type 2 diabetes published in The Lancet RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 15, 2013 /PRNewswire/ -- Data published in The Lancet showed that elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin (TRADJENTA(®)), marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (Lilly; NYSE: LLY), experienced...

2013-07-31 08:30:04

Boehringer Ingelheim and Lilly initiate post-marketing trial with a planned enrollment of more than 8,000 adults with type 2 diabetes in 24 countries RIDGEFIELD, Conn. and INDIANAPOLIS, July 31, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced enrollment of the first patient into a cardiovascular (CV) and renal outcomes trial for linagliptin (TRADJENTA) tablets. The CARMELINA(1) (CArdiovascular Safety &...

2013-06-25 08:29:43

Baseline characteristics of patients enrolled in a separate CV outcome study comparing linagliptin with glimepiride also published in the American Diabetes Association 73rd Scientific Sessions® abstract book RIDGEFIELD, Conn. and INDIANAPOLIS, June 25, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from a new pooled analysis of phase III data for the dipeptidyl peptidase-4 (DPP-4) inhibitor...

2013-06-22 12:21:03

Lower incidence of hypoglycemia observed when linagliptin is added to basal insulin in elderly patients and with linagliptin treatment vs. glimepiride, according to two presentations at the American Diabetes Association 73rd Scientific Sessions® RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two exploratory analyses assessing the risk of hypoglycemia with...

2013-06-22 12:20:56

Studies assessing linagliptin alone and in combination with metformin in people with type 2 diabetes from China, Malaysia and the Philippines presented at the American Diabetes Association 73rd Scientific Sessions® RIDGEFIELD, Conn. and INDIANAPOLIS, June 22, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced results from two phase III clinical studies that showed linagliptin in Asian adults, as monotherapy and in...